Peptide able to disrupt the protein complex between the his273 mutaded p53 protein and the oncosuppressive p73 protein in tumor cells and therapeutic uses thereof
OwnerGennaro Citro, Giovanni Blandino +2inventors
InventorsGennaro Citro, Giovanni Blandino, Sabrina Strano, Silvia Di Agostino
Life of this patent
Estimating the term…
Abstract
The present invention concerns a SIMP peptide (Short-interfering mutant p53 peptides) suitable to disrupt the protein complexes within tumour cells resulting from m-p53 and p73 proteins selectively in tumours wherein m-p53 contains His273 mutation.
Claims20
A medicament comprising a peptide having sequence FQQSSTARSATW (SEQ ID NO:
- 16).
A nucleotide sequence encoding for a peptide comprising a sequence of FQQSSTARSATW (SEQ ID NO:
- 16).
A pharmaceutical composition comprising a peptide having sequence FQQSSTARSATW (SEQ ID NO:
- 16) as an active principle in combination with one or more pharmaceutical acceptable excipients and/or adjuvants.
A method for therapy of tumours in an individual, the method comprising simultaneously, separately or sequentially administering to the individual a combination of a peptide comprising sequence FQQSSTARSATW (SEQ ID NO:
- 16) and one or more anti-tumour active principles in a suitable amount for therapy of the tumours.
A method for preparing a medicament, the method comprising providing a peptide having FQQSSTAKSATW (SEQ ID NO:
- 1) sequence in a suitable amount for treatment of tumours displaying at cellular level m-p53 His273/p73 protein complex.
A medicament comprising a peptide comprising a sequence of FQQSSTARSATW (SEQ ID NO:
- 16) in a suitable amount for treatment of tumours.
A method for treatment of tumours in an individual, the method comprising administering to the individual a suitable amount of a peptide comprising a sequence of FQQSSTARSATW (SEQ ID NO:
- 16).
Dependencies are inferred from the claim text.